Oslo - Delayed Quote NOK

Nykode Therapeutics AS (NYKD.OL)

2.6780
0.0000
(0.00%)
As of 12:04:03 PM GMT+2. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
8,679
8,679
12,902
7,168
33,963
Operating Expense
57,010
57,010
70,984
60,324
44,738
Operating Income
-48,331
-48,331
-58,082
-53,156
-10,775
Net Non Operating Interest Income Expense
6,814
6,814
8,722
3,309
166
Pretax Income
-45,513
-45,513
-44,086
-50,983
-11,118
Tax Provision
-6,692
-6,692
-8,932
-8,240
-1,704
Net Income Common Stockholders
-38,821
-38,821
-35,154
-42,743
-9,414
Diluted NI Available to Com Stockholders
-38,821
-38,821
-35,154
-42,743
-9,414
Basic EPS
-0.12
-0.12
-0.12
-0.15
-0.03
Diluted EPS
-0.12
-0.12
-0.12
-0.15
-0.03
Basic Average Shares
323,508.3330
323,508.3330
292,950
290,118.9810
286,344.8330
Diluted Average Shares
323,508.3330
323,508.3330
292,950
290,118.9810
286,344.8330
Total Operating Income as Reported
-48,331
-48,331
-58,082
-53,156
-10,775
Rent Expense Supplemental
--
--
933
753
665
Total Expenses
57,010
57,010
70,984
60,324
44,738
Net Income from Continuing & Discontinued Operation
-38,821
-38,821
-35,154
-42,743
-9,414
Normalized Income
-38,821
-38,821
-35,154
-42,828.5145
-9,511.3745
Interest Income
7,002
7,002
8,946
3,687
270
Interest Expense
188
188
224
241
130
Net Interest Income
6,814
6,814
8,722
3,309
166
EBIT
-45,325
-45,325
-43,862
-50,742
-10,988
EBITDA
-43,074
-43,074
-41,740
-48,928
-10,253
Reconciled Depreciation
2,251
2,251
2,122
1,814
734
Net Income from Continuing Operation Net Minority Interest
-38,821
-38,821
-35,154
-42,743
-9,414
Total Unusual Items Excluding Goodwill
--
--
0
102
115
Total Unusual Items
--
--
0
102
115
Normalized EBITDA
-43,074
-43,074
-41,740
-49,030
-10,368
Tax Rate for Calcs
0.0001
0.0001
0.0002
0.0002
0.0002
Tax Effect of Unusual Items
0
0
0
16.4855
17.6255
12/31/2021 - 10/7/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

52U.F Hyloris Pharmaceuticals SA
5.70
-3.72%
 
VSC.F 4SC AG
3.2100
-13.24%
 
PCIB.OL PCI Biotech Holding ASA
1.7400
-1.14%
 
ALTME.PA TME Pharma N.V.
0.0719
-0.83%
 
HPHA.DE Heidelberg Pharma AG
3.4000
+5.26%
 
VVY.AS Vivoryon Therapeutics N.V.
1.7300
+0.35%
 
ALCLS.PA Cellectis S.A.
1.3380
-1.47%
 
VICO.ST Vicore Pharma Holding AB (publ)
8.15
-4.57%
 
SOFTX.OL SoftOx Solutions AS
0.0808
-11.98%
 
ATORX.ST Alligator Bioscience AB (publ)
3.9110
-2.05%